Platelet-leukocyte mixed conjugates in patients with atrial fibrillation

Platelets

Volumn 20, Issue 4, 2009, Pages 235-241

  Alberti, Silvia ^a,b,c   Angeloni, Giulia ^a   Tamburrelli, Chiara ^a   Pampuch, Agnieszka ^a   Izzi, Benedetta ^a   Messano, Loredana ^a   Parisi, Quintino ^a   Santamaria, Matteo ^a   Donati, Maria Benedetta ^a   Gaetano, Giovanni De ^a   Cerletti, Chiara ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Atrial fibrillation; Coagulation; Leukocyte activation markers; P selectin; Platelet leukocyte conjugates

Indexed keywords

ADENOSINE DIPHOSPHATE; CD11B ANTIGEN; COLLAGEN; D DIMER; MYELOPEROXIDASE; PADGEM PROTEIN; THROMBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEART ATRIUM FIBRILLATION; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL ADHESION; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION;

EID: 67651177576     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100902954370     Document Type: Article

References (38)

1. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007; 50:2021-2028.
2. Watson T, Shantsila E. Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-166.
3. Yip HK, Chang LT, Sun C, Yang CH, Hung WC, Hang CL, Wu CJ, Chua S, Yeh KH, Chang HW. Platelet activation in patients with chronic non valvular atrial fibrillation. Int Heart J 2006;47:371-379.
4. Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis 2002;13:627-636.
5. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547-2553.
6. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: Analysis of randomized clinical trials. Stroke 2002;33:2722-2727.
7. Cerletti C, Evangelista V, de Gaetano G. P-selectin-beta 2-integrin cross-talk: A molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost 1999;82:787-793.
8. Redlich H, Vickers J, Lösche W, Heptinstall S, Kehrel B, Spangenberg P. Formation of platelet-leukocyte conjugates in whole blood. Platelets 1997;8:419-425.
9. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
10. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001;115:451-459.
11. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002;24:81-88.
12. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C, Storti S, Donati MB. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: A new effect for an old drug? J Thromb Haemost 2006;4:2593-2598.
13. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992;359:848-851.
14. Cerletti C, Evangelista V, Molino M, de Gaetano G. Platelet activation by polymorphonuclear leukocytes: Role of cathepsin G and P-selectin. Thromb Haemost 1995; 74:218-223.
15. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface- adherent platelets via sequential action of P-selectin and the beta 2-integrin CDllb/CD18. Blood 1996;88:146-157.
16. Ma YQ, Plow EF, Geng JG. P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of alphaMbeta2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils. Blood 2004;104:2549-2556.
17. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004;148:462-466.
18. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A. et al. The - 174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003;108:195-199.
19. Choudhury A, Freestone B, Patel J, Lip GY. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: A link among platelet activation, angiogenesis, and thrombosis? Chest 2007;132:1913-1919.
20. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ; Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. Europace 2007;9:335-379.
21. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001;285: 2864-2870.
22. Izzi B, Pampuch A, Costanzo S, Vohnout B, Iacoviello L, Cerletti C, de Gaetano G Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood. Thromb Haemost 2007;98:1276-1284.
23. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-1205.
24. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schömig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239-1246.
25. Marx N, Neumann FJ, Ott I, Gawaz M, Koch W, Pinkau T, Schömig A. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol 1997; 30:165-170.
26. Jurk K, Jahn UR, Van Aken H, Schriek C, Droste DW, Ritter MA, Bernd Ringelstein E, Kehrel BE. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004;91: 334-344.
27. Lowe GDO, Rumley A, Yarnell JWG, Sweetnam PM, Thomas HF. Fibrin D-dimer, von Willebrand factor and tissue plasminogen activator antigens are predictors of major ischaemic heart disease: The Caerphilly Study. Blood Coagul Fibrinolysis 1995;6:156-157.
28. Lip GYH, Lowe GDO. Fibrin D-dimer: A useful clinical marker of thrombogenesis? Clin Sci 1995;89:205-214.
29. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. In vivo tracking of platelets: Circulating degranulatedplatelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93:11877-11882.
30. Frijns CJ, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997;28:2214-2218.
31. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol 1997;99:808-816.
32. Vermylen J, Hoylaerts M, Arnout J. Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: An explanation? Circulation 2001;104:E109.
33. Straub A, Wendel HP, Azevedo R, Ziemer G The GP IIb/ IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005;27:617-621.
34. Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY. Platelet P-selectin levels in relation to plasma soluble P-Selectin and β-Thromboglobulin levels in Atrial Fibrillation. Stroke 2002;33:1237-1242.
35. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/ platelet P-selectin as indexes of platelet function in atrial fibrillation: A comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007;49:1957-1964.
36. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GDO, Beevers DG Fibrin D-dimer and betathromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996;94:425-431.
37. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001;22:1741-1747.
38. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors. Circulation 2002;106:1962-1967.